Telesis Bio Q1 2024 Adj EPS $(5.52) Misses $(0.23) Estimate, Sales $3.440M Miss $6.900M Estimate
Telesis Bio Q1 2024 Adj EPS $(5.52) Misses $(0.23) Estimate, Sales $3.440M Miss $6.900M Estimate
Telesis Bio 2024年第一季度經調整後的每股收益美元（5.52）未達到預期（0.23）美元，銷售額爲344萬美元，未達到69億美元的預期
Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23) by 2300 percent. The company reported quarterly sales of $3.440 million which missed the analyst consensus estimate of $6.900 million by 50.14 percent. This is a 45.54 percent decrease over sales of $6.316 million the same period last year.
Telesis Bio（納斯達克股票代碼：TBIO）公佈的季度虧損爲每股5.52美元，比分析師普遍預期的0.23美元（0.23美元）低2300個百分點。該公司公佈的季度銷售額爲344.4萬美元，比分析師普遍預期的69億美元低50.14％。這比去年同期的6316萬美元的銷售額下降了45.54％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。